2024-517807-35-00已完成3 期
Randomised, double-blind, placebo-controlled, active-treatment clinical trial to assess the analgesic efficacy and safety of an oral combination of ibuprofen (arginine) -tramadol HCl administered to patients with moderate to severe pain after undergoing dental surgery.
Farmalider S.A.9 个研究点 分布在 1 个国家目标入组 346 人开始时间: 2024年10月30日最近更新:
试验速览
- 阶段
- 3 期
- 状态
- 已完成
- 发起方
- 入组人数
- 346
- 试验地点
- 9
- 主要终点
- Sum of the Pain Intensity Differences from the start of administration until after 12 hours (SPID0-12h), measured through the Visual Analogue Scale (VAS).
研究概览
简要总结
To assess whether the combination of ibuprofen (arginine) and tramadol HCl 400/37.5 mg, administered orally every 6 hours to patients presenting moderate to severe pain after dental extraction (third molars), achieves better pain relief, expressed as a difference in the SPID(0-12) hours variable, than its active components administered as monotherapy and compared to placebo.
研究设计
- 分配方式
- Randomized
- 主要目的
- Fmld-iotra2-47 Fiii
- 盲法
- Double (Investigator, Monitor, Subject)
入排标准
- 年龄范围
- 18 years 至 65+ years（65+ Years, 18-64 Years）
- 接受健康志愿者
- 否
入选标准
- •Patients who provide written informed consent and who are able and willing to comply with all scheduled study visits and procedures
- •Patients ≥ 18 years at screening visit.
- •With a body mass index ≥ 18.5 and < 35 kg / m2 at the screening visit (BMI = weight/height2 = kg/m2).
- •Scheduled for surgical extraction under local anaesthetic, of at least 2 third molars, at least one of them lower, and at least one of them impacted requiring bone removal.* Inclusion criterion 4 will be verified at the screening visit.
- •That they agree not to take analgesics apart from those defined by the protocol as rescue medication and the study medication, 24 hours before the start of surgery until 48 hours after the end of the study medication.
- •Patients who achieve pain on the VAS ≥ 55 mm within the first 3 hours after the end of surgery.**Inclusion criterion 6 will be verified at visit 1 prior to randomisation.
排除标准
- •Patients with a history of allergy or hypersensitivity to study medication, rescue medication, acetylsalicylic acid or any other nonsteroidal anti-inflammatory drug (NSAID) or opioid, or any of their excipients.
- •History of drug dependency: alcohol, opiates, hypnotics, amphetamines, cocaine, hallucinogens, cannabis or synthetic drugs.
- •Patients who have consumed analgesics, muscle relaxants or anti-inflammatories (including prescription and over-the-counter drugs) 24 hours prior to the start of surgery, or 5 days prior in the case of consumption of COX-2 inhibitors, up to 48 hours after the end of the study medication.
- •Patients in treatment with any other medicinal product that should not be administered due to the risk of adverse interactions with the study medication or interference with the assessments: listed in protocol section 10.2.2 Prohibited medication.
- •Patients who have suffered complications during surgery, a duration of surgery of more than 1 hour or who have required re-anaesthesia (after reaching the appropriate level of anaesthesia).
- •Unresolved infection on the day of surgery if the surgery is severe or requires treatment with systemic antibiotic therapy.
- •Any other disease, relevant laboratory abnormality or condition that, at the discretion of the investigator, could constitute a risk to the participant or interfere with the results of the study (e.g., patients with acute pain of different origin or location at the time of surgery).
- •Patients who have received an experimental drug or used an experimental medical device within 30 days prior to the screening visit.
- •Pregnant or breastfeeding women.
- •History of asthma, bronchospasm, urticaria or angioneurotic oedema.
- •Active peptic ulcer, gastrointestinal disorders due to NSAIDs, active gastrointestinal bleeding or history of gastrointestinal bleeding.
- •Haemorrhagic diathesis or other coagulation disorders.
- •Current renal or hepatic insufficiency; or a recent history of moderate or severe impairment of renal, hepatic or cardiac function.
- •Crohn's disease or ulcerative colitis.
- •Patients who for other reasons should not receive treatment with NSAIDs or tramadol.
- •Patients who, apart from the anaesthetic procedure, cannot abstain from alcohol, psychotropic drugs or sedatives (e.g. benzodiazepines) 72 hours before the start of surgery until 48 hours after the end of the study treatment.
结局指标
主要结局
Sum of the Pain Intensity Differences from the start of administration until after 12 hours (SPID0-12h), measured through the Visual Analogue Scale (VAS).
Sum of the Pain Intensity Differences from the start of administration until after 12 hours (SPID0-12h), measured through the Visual Analogue Scale (VAS).
次要结局
- Proportion of patients using rescue medication.
- Pain intensity (PI) and pain intensity difference (PID) in scheduled assessment times up to 48 hours from the start of administration of the study medication.
- Area Under the Curve of pain intensity differences during the first 12 hours of study medication administration.
- Sum of the pain intensity differences regarding baseline, at 6 hours (SPID0-6h) from the start of the administration of the study medication.
- Patient responder rate, defined as the percentage of patients with a SPID(0-12h) ≥ δs
- Time to first pain relief (Pain intensity ↓33%).
- Total use of the different standardised levels of rescue medication from the start of treatment up to 12 and up to 48 hours later (measured in number of rescues required from each level).
- Time to the first rescue administration from the start of administration of the study medication.
- Vital signs (body temperature, heart rate and blood pressure) and general physical examination.
- Laboratory abnormalities.
- Adverse events.
研究者
Carlos Calandria
Scientific
Farmalider S.A.
研究点 (9)
Loading locations...
相似试验
招募中
不适用
Combined Intravenous Tramadol and Paracetamol Versus Intramuscular Pethidine for Pain Relief During the First Stage of Labor. Compare the Efficacy and Adverse EffectsNCT07264309Zohar Nachum140
招募中
3 期
Phase III, double-blind, randomised, placebo- and active treatment-controlled clinical trial to evaluate the analgesic efficacy and safety of a combination of ibuprofen (arginate)-tramadol hydrochloride 400-37.5 mg, administered intravenously to patients with acute severe postoperative pain.2023-505687-11-00Farmalider S.A.216
进行中（未招募）
3 期
Tramadol Versus Placebo and Morphine in the Management of Post-Operative Pain AbdominoplastyPain ManagementNCT03774836Avenue Therapeutics, Inc.360
已完成
不适用
Intrathecal Nalbuphine Versus Intrathecal Tramadol in Subarachnoid Block for Lower Limb Orthopaedic SurgeriesAdjuvants, AnesthesiaSubarachnoid BlockNCT07294352CMH Lahore Medical College and Institute of Dentistry40
尚未招募
2 期
Comparison of control of shivering occuring after giving spinal anesthesia by using regularly used opioids like butorphanol & tramadolCTRI/2023/08/056817Pondicherry Institute of Medical Sciences